Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
Devyser Diagnostics AB has entered an in vitro diagnostic development agreement with Illumina, Inc....
On October 26th, we hosted an insightful webinar by Prof. Milan Macek (M.D., DSc.), where he...
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in...
Meet Silvia Borras, a Development Lead and Clinical Scientist in Genetics and Molecular Pathology...
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further...
Dear Devyser network, partners, and valued customers,
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote...
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including...